NYSE:PRME Prime Medicine 11/12/2024 Earnings Report $4.07 -0.01 (-0.25%) Closing price 04:00 PM EasternExtended Trading$4.06 -0.02 (-0.37%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Prime Medicine EPS ResultsActual EPS-$0.44Consensus EPS -$0.43Beat/MissMissed by -$0.01One Year Ago EPSN/APrime Medicine Revenue ResultsActual Revenue$0.21 millionExpected Revenue$55.00 millionBeat/MissMissed by -$54.79 millionYoY Revenue GrowthN/APrime Medicine Announcement DetailsQuarterDate11/12/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Prime Medicine Earnings HeadlinesCathie Wood’s ARK ETF adjusts stock positions, buys PRME and TWSTSeptember 9 at 8:07 PM | investing.comPrime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.September 12 at 2:00 AM | Banyan Hill Publishing (Ad)Prime Medicine Unveils New Prime Editing AdvancementsSeptember 8, 2025 | msn.comPrime Drink Group Terminates Rights Offering and Announces Private PlacementSeptember 4, 2025 | globenewswire.comPrime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comSee More Prime Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email. Email Address About Prime MedicinePrime Medicine (NYSE:PRME) (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics. Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases. The company is advancing several preclinical and clinical candidates designed to correct mutations in genes associated with inherited diseases, as well as to modulate immune cell function for the treatment of cancer and chronic inflammatory conditions. Through strategic collaborations and internal discovery programs, Prime Medicine seeks to establish a diverse pipeline of genome-editing therapies with potential for durable clinical benefits. Founded in 2021 as a spin-out from leading academic laboratories at the Broad Institute of MIT and Harvard, Prime Medicine is headquartered in Cambridge, Massachusetts. Since inception, the company has assembled a team of experts in molecular biology, delivery science, and translational medicine, and has secured substantial venture capital backing to propel its platform toward clinical milestones. By leveraging its scientific heritage and industry partnerships, Prime Medicine is committed to transforming the treatment landscape for patients with serious genetic and immune-mediated diseases.View Prime Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
